About alpelisib
PI3K-alpha inhibitor
Used for
- With fulvestrant for advanced or metastatic hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation, after progression on endocrine therapy.
Usual adult dose
Usual dose is 300 mg by mouth once daily with food; treatment may be reduced or interrupted for side effects.
Common side effects
- High blood sugar
- Diarrhea
- Rash
- Nausea and decreased appetite
Important warnings
- Can cause severe high blood sugar, including ketoacidosis.
- Severe skin reactions and serious allergic reactions can occur.
- Diarrhea may become severe and cause dehydration.
- Monitor blood sugar and skin symptoms during treatment.
Pregnancy
Can harm an unborn baby. Avoid pregnancy during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong CYP3A4 inducers may reduce alpelisib effectiveness.
- BCRP substrates may have increased exposure; monitor for side effects.
- Avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.